Live
- New Mizoram Guv likely to take charge next week
- Barroz 3D Movie Review: A Visual Treat for Mohanlal Fans, Mixed for Others
- Donate Blood, Save Lives: BJP Hosts Mega Blood Donation Camp in Aiza
- Azerbaijani Airliner Crashes Near Aktau, Kazakhstan: 32 Survive, Over 30 Feared Dead
- Union Minister Bandi Sanjay Kumar to Visit Jogulamba Gadwal District on December 27, 2024
- Gadwal Lawyers' United Protest: Opposition to District Court Relocation Gains Momentum
- Christmas Celebrations in Jogulamba Gadwal: A Festival of Unity, Charity, and Joy
- Lawyers Seek MP DK Aruna’s Intervention to Prevent District Court Relocation
- Israel, Hamas trade blame for delays in reaching Gaza ceasefire deal
- PM Modi, President Murmu extend Hanukkah greetings to Israeli counterparts
Dr Reddy's launches drug in US
Dr Reddy's Laboratories Ltd on Friday announced the launch of Trientine Hydrochloride capsules in the US market.
Hyderabad: Dr Reddy's Laboratories Ltd on Friday announced the launch of Trientine Hydrochloride capsules in the US market.
Trientine works by removing copper from the blood. It is used to treat Wilson's disease, a genetic metabolic defect that causes excess copper to build up in the body. In a regulatory filing, Dr Reddy's Laboratories announced the launch of Trientine Hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) capsules approved by the US Food and Drug Administration (USFDA). "We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners," Chief Executive Officer and Head of Dr Reddy's North America Generics Marc Kikuchi said.
The Syprine brand and generic products had US sales of approximately $94.2 million MAT (Moving Annual Total) for the most recent twelve months ending in December 2019, according to IMS Health. Dr Reddy's Trientine Hydrochloride capsules USP, 250 mg are available in 100 count bottles, the filing said.
